Tìm theo
Finasteride
Các tên gọi khác (3) :
  • (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
  • Finasterida
  • Finasteridum
Thuốc hỗ trợ trong điều trị bệnh đường tiết niệu
Thuốc Gốc
Small Molecule
CAS: 98319-26-7
ATC: D11AX10, G04CB01
ĐG : Accord Healthcare , http://www.accord-healthcare.com
CTHH: C23H36N2O2
PTK: 372.5441
An orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
Phân tử khối
372.5441
Monoisotopic mass
372.277678406
InChI
InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
InChI Key
InChIKey=DBEPLOCGEIEOCV-WSBQPABSSA-N
IUPAC Name
(1S,2R,7R,10S,11S,14S,15S)-N-tert-butyl-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide
Traditional IUPAC Name
finasteride
SMILES
[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C
Độ tan chảy
252-254 °C
Độ hòa tan
11.7 mg/L
logP
3.03
logS
-5.3
pKa (strongest acidic)
14.53
pKa (Strongest Basic)
2.22
PSA
58.2 Å2
Refractivity
108.2 m3·mol-1
Polarizability
43.93 Å3
Rotatable Bond Count
2
H Bond Acceptor Count
2
H Bond Donor Count
2
Physiological Charge
0
Number of Rings
4
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Finasteride is a synthetic 4-azasteroid compound. This drug is a competitive and specific inhibitor of Type II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). Two distinct isozymes are found in mice, rats, monkeys, and humans: Type I and II. Each of these isozymes is differentially expressed in tissues and developmental stages. In humans, Type I 5a-reductase is predominant in the sebaceous glands of most regions of skin, including scalp, and liver. Type I 5a-reductase is responsible for approximately one-third of circulating DHT. The Type II 5a-reductase isozyme is primarily found in prostate, seminal vesicles, epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT. Although finasteride is 100-fold more selective for type II 5a-reductase than for the type I isoenzyme, chronic treatment with this drug may have some effect on type I 5a-reductase.
Cơ Chế Tác Dụng : An orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia. [PubChem] The mechanism of action of Finasteride is based on its preferential inhibition of Type II 5a-reductase through the formation of a stable complex with the enzyme. Inhibition of Type II 5a-reductase blocks the peripheral conversion of testosterone to DHT, resulting in significant decreases in serum and tissue DHT concentrations, minimal to moderate increase in serum testosterone concentrations, and substantial increases in prostatic testosterone concetrations. As DHT appears to be the principal androgen responsible for stimulation of prostatic growth, a decrease in DHT concentrations will result in a decrease in prostatic volume (approximately 20-30% after 6-24 months of continued therapy). In men with androgenic alopecia, the mechanism of action has not been fully determined, but finasteride has shown to decrease scalp DHT concentration to the levels found in hairy scalp, reduce serum DHT, increase hair regrowth, and slow hair loss.
Dược Động Học :

▧ Volume of Distribution :
* 44 to 96 L
▧ Protein binding :
Approximately 90%
▧ Metabolism :
Drug is extensively metabolized, primarily in the liver via CYP3A4. Two metabolites have been identified with ≤20% of the activity of finasteride.
▧ Route of Elimination :
Following an oral dose of 14C-finasteride in man (n = 6), a mean of 39% (range, 32 to 46%) of the dose was excreted in the urine in the form of metabolites; 57% (range, 51 to 64%) was excreted in the feces. Urinary excretion of metabolites was decreased in patients with renal impairment. This decrease was associated with an increase in fecal excretion of metabolites.
▧ Half Life :
4.5 hours (range 3.3-13.4 hours)
▧ Clearance :
* 165 mL/min [healthy young subjects]
Chỉ Định : For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for surgery including transurethral resection of the prostate. Also used for the stimulation of regrowth of hair in men with mild to moderate androgenetic alopecia (male pattern alopecia, hereditary alopecia, common male baldness).
Liều Lượng & Cách Dùng : Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Propecia 1 mg tablet
    Giá bán buôn : USD >2.74
    Đơn vị tính : tablet
  • Biệt dược thương mại : Finasteride 5 mg tablet
    Giá bán buôn : USD >3.19
    Đơn vị tính : tablet
  • Biệt dược thương mại : Proscar 5 mg tablet
    Giá bán buôn : USD >3.64
    Đơn vị tính : tablet
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Finastid
  • Công ty :
    Sản phẩm biệt dược : Finpecia
  • Công ty : Merck
    Sản phẩm biệt dược : Propecia
  • Công ty :
    Sản phẩm biệt dược : Proscar
Đóng gói
... loading
... loading